|
Market Closed -
Nasdaq
20:00:00 27/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 11.42 USD | +0.84% |
|
+0.22% | -43.89% |
| 09-29 | Keros Therapeutics Expects $20 Million Milestone Payment From Takeda | MT |
| 09-29 | Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda | CI |
Company Valuation: Keros Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,369 | 1,323 | 1,191 | 641.2 | 620.3 | 226.5 | - | - |
| Change | - | -3.39% | -9.94% | -46.17% | -3.27% | -63.48% | - | - |
| Enterprise Value (EV) | 1,369 | 1,323 | 860 | 81.3 | 620.3 | 226.5 | 226.5 | 226.5 |
| Change | - | -3.39% | -34.98% | -90.55% | 662.95% | -63.48% | 0% | 0% |
| P/E | -23.2x | -11.6x | -7.65x | -3.17x | 8.85x | -2.06x | -1.83x | -2.45x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.82x | -0x | 0x | -0.1x | 0.1x |
| Capitalization / Revenue | 68.1x | - | 7,889x | 181x | 2.54x | 14.6x | 16.5x | 5.07x |
| EV / Revenue | 0x | - | 0.01x | 0x | 0x | 14.6x | 16.5x | 5.07x |
| EV / EBITDA | - | - | -0x | -0x | 0x | -2.05x | -2.6x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -1.88x | -1.47x | -1.64x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -2.28x | -1.8x | -1.92x |
| FCF Yield | -4.61% | -5.39% | -10.7% | -25.3% | 17.1% | -43.8% | -55.4% | -52% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.52 | -4.15 | -5.2 | -5 | 2.3 | -5.537 | -6.236 | -4.657 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 20.1 | - | 0.151 | 3.55 | 244.1 | 15.57 | 13.73 | 44.69 |
| EBITDA 1 | - | - | -169.1 | -209.6 | 69.08 | -110.4 | -87.15 | - |
| EBIT 1 | -56.37 | -114.8 | -169.9 | -210.8 | 67.57 | -120.5 | -154.3 | -137.9 |
| Net income 1 | -58.74 | -104.7 | -153 | -187.4 | 87.01 | -110.4 | -147.4 | -133 |
| Net Debt | - | - | -331.1 | -559.9 | - | - | - | - |
| Reference price 2 | 58.51 | 48.02 | 39.76 | 15.83 | 20.36 | 11.42 | 11.42 | 11.42 |
| Nbr of stocks (in thousands) | 23,399 | 27,543 | 29,959 | 40,507 | 30,466 | 19,827 | - | - |
| Announcement Date | 09/03/22 | 03/03/23 | 28/02/24 | 26/02/25 | 04/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.06x | - | - | -.--% | 227M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 23.98x | 26.33x | 15.57x | 0.31% | 38.07B | |
| Weighted average by Cap. | 26.53x | 25.23x | 15.68x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- KROS Stock
- Valuation Keros Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
